Home › Pancreatic Cancer › NCT06148298
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
RecruitingObservational study
Cell-free Chromatin Immunoprecipitation (CfChIP) from Blood Plasma As a Diagnostic and Prognostic Tool in Pancreatic Ductal Adenocarcinoma
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * 18 years old or older * Pancreatic cancer patients Exclusion Criteria: * Children may not register * Persons who are unable to consent may not register
About the study
The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples.
This is a Non-Human Subject Research study. All participants are de-identified.
What is being tested
- Non-Human Subject Research study. (other)
Sponsor: University of Central Florida · Participants: 24 · Started: May 24, 2023
Contact the study team
- Amoy Fraser, PhD, CCRP, PMP · Phone: 4072668742
- Erica Martin, B.S. · Phone: 4072668742
Official record on ClinicalTrials.gov — NCT06148298
Locations in the U.S.
| Florida | University of Central Florida, Orlando |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.